EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women

Davide Serrano, Matteo Lazzeroni, Roberta Rizzo, Patrizia Gnagnarella, Gaetano Aurilio, Elisa Colombo, Aliana Guerrieri-Gonzaga, Harriet Johansson, Stefania Zovato, Mariateresa Nardi, Anna Matteraglia, Matilde Pensabene und 12 weitere

European Journal of Cancer · 2026-11 · 248 · 117784

DOI: 10.1016/j.ejca.2026.117784 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Davide Serrano und 23 weiteren Autor:innen. Beteiligte Einrichtung: European Institute of Oncology IRCCS, Milano, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen, Caloric Restriction, Antineoplastic Agents, Hormonal. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Government Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTamoxifenCaloric RestrictionAntineoplastic Agents, HormonalLife StyleRisk Reduction BehaviorHumansFemaleMiddle AgedSex Hormone-Binding GlobulinAdultQuality of LifeIntermittent FastingRisk Factors

Stichwörter der Autor:innen

Breast cancerIntermittent caloric restrictionLow-dose tamoxifenPrevention medicineSHBGSerum biomarkers

Substanzen

Sex Hormone-Binding GlobulinTamoxifenAntineoplastic Agents, HormonalSHBG protein, human

Autor:innen und Institutionen

  • European Institute of Oncology IRCCS, Milano, Italy.
  • European Institute of Oncology IRCCS, Milano, Italy. Electronic address: matteo.lazzeroni@ieo.it.
  • Istituto Oncologico Veneto (IOV), Padova, Italy.
  • Istituto Nazionale Tumori G. Pascale, Napoli, Italy.
  • E.O. Galliera - Ospedale Genova, Italy.

Förderung

  • Italian Government Ministry of Health

Zitieren

APA

Serrano, D., Lazzeroni, M., Rizzo, R., Gnagnarella, P., Aurilio, G., Colombo, E., Guerrieri-Gonzaga, A., Johansson, H., Zovato, S., Nardi, M., Matteraglia, A., Pensabene, M., Buccolo, S., Pistelli, L., Giancarli, G., Carbone, A., Aristarco, V., Macis, D., Accornero, C. A., …, & Bonanni, B. (2026). Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women. European Journal of Cancer, 248, 117784. https://doi.org/10.1016/j.ejca.2026.117784

Vancouver

Serrano D, Lazzeroni M, Rizzo R, Gnagnarella P, Aurilio G, Colombo E, et al. Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women. European Journal of Cancer. 2026;248:117784. doi:10.1016/j.ejca.2026.117784

BibTeX
@article{Serrano2026,
  author = {Serrano, Davide and Lazzeroni, Matteo and Rizzo, Roberta and Gnagnarella, Patrizia and Aurilio, Gaetano and Colombo, Elisa and Guerrieri-Gonzaga, Aliana and Johansson, Harriet and Zovato, Stefania and Nardi, Mariateresa and Matteraglia, Anna and Pensabene, Matilde and Buccolo, Simona and Pistelli, Luigi and Giancarli, Giorgia and Carbone, Alessio and Aristarco, Valentina and Macis, Debora and Accornero, Chiara A and Merli, Davide and Salè, Emanuela Omodeo and DeCensi, Andrea and Gandini, Sara and Bonanni, Bernardo},
  title = {Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117784},
  doi = {10.1016/j.ejca.2026.117784}
}
Kostenlos starten →